1. In Vivo

Biogen Idec Taps Exelixis' Scangos To Be New CEO

Exelixis’s long-time CEO George Scangos, PhD, is taking the the helm of Biogen Idec. The move is counterintuitive, both for the commercial stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.

Shortly after the market closed on June 30, Biogen Inc. and Exelixis Inc. confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos, PhD, taking the helm of the Big Biotech July 15. The move is counterintuitive, both for the commercial-stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.

Scangos, a scientist turned entrepreneur, is best known for making deals of all stripes at a biotech with experimental medicines....

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.